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Abstract The clinical applications of cardiovascular mag-
netic resonance imaging with contrast enhancement are
expanding. Besides the direct visualisation of viable and
non-viable myocardium, this technique is increasingly used
in a variety of cardiac disorders to determine the exact
aetiology, guide proper treatment, and predict outcome and
prognosis. In this review, we discuss the value of
cardiovascular magnetic resonance imaging with contrast
enhancement in a range of cardiac disorders, in which this
technique may provide insights beyond the scope of
myocardial viability.
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Introduction
Contrast-enhancement (CE) cardiovascular magnetic reso-
nance (CMR) imaging is a technique that was initially
developed to distinguish viable from non-viable myocardium
following myocardial infarction (MI) [1–3]. In addition,
CE-CMR is increasingly used for tissue characterisation in
a broad spectrum of clinical applications, which are
illustrated and discussed in this manuscript. Besides its
ability to measure the size of myocardial scars or fibrosis,
CE-CMR can determine the exact aetiology of disease, guide
proper treatment, and predict outcome and prognosis in a
variety of cardiac diseases; examples may be (non)-ischaemic
cardiomyopathies, myocarditis, intracardiac masses, and
myocardial involvement in systemic diseases.
Brief technical background of CE-CMR
The technique of CE-CMR imaging involves an intravenous
injection of a contrast agent (e.g., gadolinium at a preferred
dose of 0.2 mmol/kg body weight) followed by an ECG-gated
T1-weight pulse sequence 10–15 min after the injection [4].
The timing of the image acquisition is of paramount
importance, as too early image acquisition reduces the
difference in contrast between normal and damaged myo-
cardium (such as scar or fibrosis) because of an insufficient
washout of contrast medium from the normal myocardium;
too late image acquisition, on the other hand, may result in
an excessive washout from damaged myocardial tissue that
leads to an inferior signal-to-noise ratio [2]. The typical pulse
sequence for CE-CMR imaging is a segmented T1-weighted
inversion-recovery-prepared fast gradient-echo sequence. An
inversion-recovery pulse is used to null the signal of normal
myocardium in order to optimise the difference between
normal and damaged myocardial areas (which still contain
contrast medium) (Fig. 1).
The optimal inversion time depends on the contrast
clearance from the normal myocardium which may show
considerable inter-patient variability, depending on several
factors such as the patient weight, and left ventricular (LV) or
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renal function. Therefore, just before image acquisition, the
inversion time is optimised on a per-patient basis using low-
resolution scout images at mid-ventricular level with increasing
inversion times at intervals of 30 ms, from which the optimal
inversion time can be derived [4]. The process is synchronised
to the R-wave of the ECG, and mid-diastolic images are
acquired every other heart beat during breath-hold [3].
CE-CMR after myocardial infarction
Myocardial infarction (MI) occurs after coronary occlusion
of at least 20–30 min (without sufficient collateral blood
supply to the affected myocardium) [5]. In the early phase
of myocardial infarction, cellular degradation in the
infarcted myocardium results in an increase in the perme-
ability and enlargement of the extravascular space (oedema),
and thus, an increased distribution volume for the CMR
contrast agent. Later on, due to different wash-in and wash-
out kinetics, myocardial scars retain contrast agents longer
than normal myocardium. The net result of both mechanisms
is that infarcted myocardium appears bright on CE T1-
weighted images.
CE in patients with MI generally shows a typical pattern
that is related to the perfusion area of the culprit vessel.
Myocardial changes (and thus CE) of the subendocardium
can generally be found which may extend to a transmural
distribution in cases with prolonged coronary occlusion. In
patients with prior MI, there is a high inter-observer
agreement for the assessment of presence and extent of
CE [6–8]. In addition, presence, location, and extent of CE
correspond well with histology [6–8].
In patients after MI, the assessment of myocardial
viability can provide clinically important information to
guide further treatment because only viable myocardium
may benefit from revascularisation [9]. Generally, a
standardised 17-myocardial segment model is used to
report the results of viability assessment by CE-CMR
(Fig. 2) [10]. In addition, quantification of infarcted tissue
helps to prognosticate left ventricular remodelling [11]. In
this respect, the transmural extent of infarcted tissue as
determined by CE-CMR (Figs. 2b and 3a, b) has been
shown to be a powerful predictor of the contractile
response to both medical therapy and myocardial revascu-
larisation [12].
Increasing interest is also laid on the assessment of
characteristics of infarcted myocardial tissue as potential
predictor of life-threatening ventricular arrhythmias. Recently,
a highly significant relation between inferior MI and
Fig. 1 Schematic figure for inversion time (TI) mapping. Following
the ECG trigger, an inversion-recovery (IR) pulse is applied. Before
image acquisition, low-resolution TI scout images at mid-ventricular
level with increasing TI (interval TI, 30 ms) are performed. The
optimal time to inversion (TI0) is defined visually as the inversion time
at which the uninfarcted myocardium (1) is nulled; infarcted
myocardium (2)
Fig. 2 Bulls eye scheme according to the 17-segmental model,
demonstrating CE characteristics post-myocardial infarction. a
Assignment of the 17 segments to one of the three major coronary
arteries, with segment 1, 2, 7, 8, 13, 14, and 17 corresponding to the
left anterior descending coronary artery; segments 3, 4, 9, 10, and 15
corresponding to the right coronary artery when it is dominant; and
segments 5, 6, 11, 12, and 16 are assigned to the left circumflex artery.
b Transmural inferior MI. c Inferoseptal MI with a core zone (white
area) and a peri-infarction zone (grey area). d Inferior MI with
microvascular obstruction (black area in myocardial infarction area)
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ventricular arrhythmias was observed [13]. Multivariate
analysis of data from 91 patients suggested that the
heterogeneity of infarcted tissue (also called peri-infarct
zone or border zone; Fig. 2c) can be an important predictor
of spontaneous ventricular arrhythmias [14].
The area of CE tends to be larger during the acute
phase of MI (first week) and progressively decreases in
size during the healing phase (1–4 weeks), until it
reaches the state of a healed myocardial infarction (after
4 weeks) [15]. These observations are consistent with the
established pathological understanding of remodelling
after MI: during the acute phase, there is myocardial
oedema which subsequently regresses while the necrotic
myocardium is replaced by scar tissue. Experimental
studies have revealed that final MI size is strongly
influenced by the extent of the oedema in the acute phase,
which is also called area at risk (AAR). By combining T2-
weighted images to visualise myocardial oedema (and thus
the AAR) and CE-CMR imaging to visualise scar (the
final infarct size), a myocardial salvage index can be
calculated by subtracting the infarct size from the AAR
[16]. The myocardial salvage index has recently shown to be
independently associated with adverse LV remodelling and
early ST-segment resolution, and may represent an interesting
parameter for the assessment of novel reperfusion strategies in
patients with myocardial infarction (trial registration number
NL19151.044.07).
In addition, some patients develop microvascular
obstruction within the ischaemic myocardial region in the
acute phase of an MI [17]. Microvascular obstruction is
represented by a dark zone within the infarcted region,
usually located in the subendocardium because the contrast
medium does not reach this area (Figs. 2d and 3c, d). Its
presence is associated with greater LV remodelling and
inferior clinical outcome [18, 19].
CE-CMR in nonischaemic cardiomyopathy
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (CMP) is a primary myocar-
dial disease characterised by focal (mostly septal) or diffuse
LVwall thickening (with or without LVoutflow obstruction).
Fig. 3 CE-CMR patterns post-
myocardial infarction. a, b CE
short-axis and long-axis view
showing transmural inferior
infarction (black arrow).
c, d Short-axis and long-axis
view showing an inferior
infarction with microvascular
obstruction (white arrow)
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Myofibrillar hypertrophy and disarray [20] and myocardial
fibrosis have been described histologically [3]. Inadequate
capillary density and intimal hyperplasia of intramural
coronary arteries, which were also seen in such patients,
may contribute to myocardial ischaemia [3]. There are
predilection patterns of CE in patients with hypertrophic
CMP: more than 80% of patients exhibit patchy fibrosis at
the right ventricular insertion points and in the anteroseptal
wall in the region of characteristic septal thickening
(Figs. 4a and 5a, b) [21, 22]. Myocardial fibrosis, however,
is also located in non-hypertrophic segments [23, 24]. As
the amount of CE in hypertrophic CMP often corresponds
with functional parameters and the frequency of cardiac
events, CE-CMR may potentially be useful for risk
stratification [25]. However, data regarding the prognostic
value of these findings remain scarce; therefore, further
research is warranted [26].
Presence and extent of CE following percutaneous
transseptal myocardial ablation (by alcohol injection) for
the treatment of significant LV outflow tract obstruction
indicate the location and extent of therapeutic myocardial
tissue destruction [27].
Idiopathic dilated cardiomyopathy
Idiopathic dilated CMP is characterised by dilation and
impaired contractility of the left ventricle or both ventricles
in the absence of abnormal loading conditions (e.g., arterial
hypertension, valvular disease), and/or a CMP with a
distinct cause (e.g., ischaemic heart disease; peripartum
cardiomyopathy; toxin-, chemotherapy-, or tachycardia-
induced cardiomyopathy; certain endocrinopathies) [1].
Histology is nonspecific, and a variety of myocardial
tissue alterations may occur or coexist, including myocyte
hypertrophy and segmental or diffuse interstitial fibrosis.
Current CE-CMR techniques are unlikely to detect
diffuse fibrosis due to limited voxel resolution [28].
Myocardial fibrosis in idiopathic dilated CMP is mostly
seen in the LV midwall with septal predominance and a
linear pattern (Figs. 4b and 5c, d); however, it has
occasionally been described at subendocardial and sub-
epicardial locations with a more patchy pattern [23]. Of
note, in various studies, the prevalence of myocardial
fibrosis varied from 13% to 62% [29, 30]. It has been
suggested that the degree of CE may correlate with
functional impairment of the LV [31]. There are prelim-
inary data demonstrating that the presence of CE is
associated with an unfavourable clinical outcome and
may be a predictor of sudden death in patients with
idiopathic dilated CMP [29, 32, 33].
Arrhythmogenic right ventricular cardiomyopathy
The arrhythmogenic right ventricular cardiomyopathy
(ARVC) is characterised by structural and functional
abnormalities, with progressive fibrous and fatty infiltra-
tion involving variable regions of the right and left
ventricular myocardium. This process finally leads to
progressive RV failure and ventricular tachyarrhythmia
[23]. Diagnosis of this condition remains a challenge, with
nonspecific abnormalities on echocardiographic and
angiographic examinations. Endomyocardial biopsy has a
low sensitivity, as samples are usually taken from the
septum, a region that is infrequently involved [23].
Information from CE-CMR may help to guide targeted
endomyocardial biopsies. Predilection patterns with mid-
wall CE are found in the basal anterior region (Fig. 4c)
and/or the RV outflow tract. These patterns of fibrosis
correlate with fibro-fatty replacement of the myocardium
at histological assessment and predict induction of
ventricular tachycardia during electrophysiological stud-
ies. As the presence of ARVC cannot be ruled out based
on CMR findings alone, standardised guidelines have been
proposed which define major and minor criteria, including
morphological, histological, electrocardiographic, func-
tional, and genetic characteristics [34, 35].
Fig. 4 Bulls eye scheme according to the 17-segmental model,
demonstrating typical CE patterns in nonischaemic cardiomyopathies.
a Hypertrophic cardiomyopathy with predilection CE (i.e., fibrosis)
pattern at the right ventricular insertion points (I) and anteroseptal (II).
Myocardial fibrosis is also located in non-hypertrophic segments. b
Idiopathic dilated cardiomyopathy with CE predominantly located in
the midwall with septal predominance. c Arrhythmogenic right
ventricular cardiomyopathy with midwall CE found in the basal
anterior region. CE is also found in the right ventricular outflow
tract
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CE-CMR in myocarditis
Myocarditis
Myocarditis is an acute or chronic inflammatory disease of
the myocardium, which can be caused by viruses or
initiated by post-infectious immune or primarily organ-
specific autoimmune responses [36]. Patients generally
recover or infrequently develop dilated CMP, sometimes
even with life-threatening complications including severe
heart failure and malignant arrhythmias [37]. Diagnosis of
myocarditis is challenging because of a diverse clinical
presentation and a limited sensitivity of endomyocardial
biopsies, but may be facilitated by use of CE-CMR or
myocardial global relative enhancement CMR [38, 39].
Presence of CE has been reported in 44–95% of patients
with myocarditis, [40, 41] indicating areas of myocardial
damage with a sensitivity of 100% and a specificity of 90%
(compared with histopathology) [40]. In acute myocarditis,
CE is frequently located in the lateral wall, originating from
the epicardium. The subendocardium is generally not
involved, with the exception of eosinophilic myocarditis
which frequently involves the endomyocardium (Fig. 6a)
[23, 42]. In chronic myocarditis, besides an increased
oedema on T2-weighted imaging, an increased global
relative enhancement is a common finding as confirmed
in immunohistological analyses [38]. CE-CMR identified
areas of myocardial damage in 70% of patients with biopsy-
proven chronic myocarditis and showed a predilection
pattern (LV midwall and/or subepicardial). CE may also
help to guide targeted endomyocardial biopsies. In
myocarditis, CE may provide additional information that
could help to differentiate between viral origins; in the
majority of parvovirus B19 patients, CE is found in
the lateral free wall, while in patients with HHV6
myocarditis, CE frequently involves the interventricular
septal midwall [43]. In addition, we recently studied a
limited number of patients with chronic fatigue syndrome
and concomitant Ebstein Barr virus or cytomegalovirus
myocarditis who showed a certain predilection of the
septal region in the presence of CE. Inflammatory activity
on T2-weighted imaging and myocardial fibrosis on CE-
CMR may have relevant prognostic implications in acute
and chronic myocarditis and may ultimately serve as a tool
Fig. 5 CE-CMR patterns in
nonischaemic cardiomyopathies.
a, b CE short-axis and long-axis
view showing hypertrophic
cardiomyopathy with patchy CE
septal and in the right ventricular
insertion points (black arrow). c,
d Short-axis and long-axis view
showing dilated cardiomyopathy
with CE having septal midwall
predominance (white arrow)
240 Neth Heart J (2011) 19:236–245
to triage patients [44]. In addition, cardiac function and
regression of myocardial changes can be well observed
with CMR.
CE-CMR in intracardiac masses
Intracardiac masses can be characterised as thrombi,
primary benign or malignant tumours or metastases of the
heart. Along with cine gradient echo and both T1-weighted
and T2-weighted CMR images, CE-CMR imaging (with its
capability of characterising tissue) can provide important
additional information in the evaluation of intracardiac
masses. A correct suggestion for the aetiology of intracar-
diac masses has been reported in 75% of cases by CMR,
compared with 29% by echocardiography [45]. Cardiac
thrombi are overall the most frequent intracardiac masses
[46, 47]. Myxomas, the most common benign tumours of
the heart, have a high signal intensity on T2-weighted
images (due to a high extracellular water content) and will
generally enhance heterogeneously with CE (reflecting
varying components of myxoid, haemorrhagic, cystic, calci-
fied, and fibrous tissue); thrombi—on the other hand—will
generally not enhance [48, 49]. Features of malignant
tumours at CMR are invasive spreading, involvement of
the right side of the heart, heterogeneous tissue with low and
high signal intensities on T1 images, a diameter greater than
5 cm, and/or the presence of increased CE (as a result of an
increased vascularisation).
CE-CMR in systemic diseases
Sarcoidosis
Cardiac involvement in sarcoidosis, a multisystem granu-
lomatous disorder of unknown aetiology, is clinically often
asymptomatic (95%) while autopsy revealed cardiac mani-
festation in up to 60% [50]. Advanced sarcoidosis leads to
septal thinning, systolic and diastolic dysfunction, and
pericardial effusion, which can easily be detected with
echocardiography [4]. Early sarcoidosis, however, is more
challenging to diagnose, and CMR can be very useful in
this context. During the acute stage of this disease, regions
of active inflammation and oedema are visible on T2-
weighted images as areas of increased signal intensity.
During the chronic stage, CE will typically appear as a
midwall or epicardial nonischaemic pattern (Fig. 6b), but
occasionally, subendocardial or transmural CE may be
observed, mimicking a pattern of post-MI. CE has been
found in 50% of all patients diagnosed with sarcoidosis
[51]. CE-CMR may also be useful to evaluate the response
to therapy. In a CMR study of 16 patients with sarcoidosis,
CE was markedly diminished 1 month after the initiation of
Fig. 6 Bulls eye scheme according to the 17-segmental model,
demonstrating typical CE patterns in myocarditis and cardiac
involvement of other diseases. a Myocarditis with CE frequently
located in the lateral wall originating from the epicardium (I). CE
patterns in myocarditis differ according to viral origin, with parvovirus
B19 having CE in the lateral free wall (I), HHV6 having CE
frequently in the interventricular septal midwall (II), and chronic
fatigue syndrome myocarditis having CE anteroseptal and inferoseptal
(III). b Sarcoidosis with CE midwall or epicardial; however,
subendocardial or transmural CE may be observed. c Amyloidosis,
usually with a global diffuse CE pattern, frequently involving the
subendocardium. d Chagas’ disease with CE epicardial or midwall,
with a predilection pattern inferolateral. e Pulmonary hypertension
with CE involving the right ventricular insertion points and the
interventricular septum. fMuscular dystrophy with CE observed in the
midwall. g Chloroquine-induced cardiomyopathy with hypertrophy
and accompanying CE in the basal septum (I) and the right ventricular
insertion points (I)
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steroid therapy [51]. CE in sarcoidosis patients may be
associated with future adverse events (including cardiac
death), but confirmation in larger patient cohorts is required
[50].
Amyloidosis
Both primary and secondary amyloidosis are characterised
by extracellular deposition of fibrillar proteins, [1] which
may lead to restrictive cardiomyopathy with an initially
preserved systolic LV function [52]. In cardiac amyloidosis,
CE is commonly found as a result of the expansion of
interstitial space and some endomyocardial fibrosis, [53]
leading to a usually global and diffuse CE pattern [4].
Although the subendocardium is commonly involved (as
in ischaemic heart disease), the distribution of CE is not
related to a particular coronary perfusion area (Fig. 6c)
[4].
Chagas’ disease
The parasitic protozoan Trypanosoma cruzi causes Chagas’
disease, which is endemic in the Latin American region [4].
During chronic disease, the heart is the most frequently
affected organ, and patients present with refractory heart
failure, disorders of the conduction system, or ventricular
tachycardia [3, 54]. The fundamental pathological process-
es include an inflammatory response, cellular damage with
a broad variation of intensity (minimal alterations up to
extensive necrosis), and fibrosis [55]. Early cardiac
involvement may be detected by CE-CMR before the onset
of symptoms [56]. CE is often seen epicardially or in the
LV midwall with an inferolateral predilection pattern
(Fig. 6d), but other regions—including the apex—may also
sometimes be affected [4].
Pulmonary hypertension
Pulmonary arterial hypertension, both primary and sec-
ondary, is characterised by an increased pulmonary
vascular resistance that results in pressure overload on
the right ventricle [57]. Cine CMR permits accurate
assessment of RV mass and volumes which is often
difficult to accomplish with other imaging modalities [3].
Myocardial CE is frequently observed in patients with
severe symptomatic pulmonary artery hypertension with
predilection patterns involving both right ventricular
septal insertion points and the interventricular septum
(Fig. 6e). CE in the interventricular septum was found to
be associated with septal bowing (on cine CMR), and the
extent of CE correlated inversely with right ventricular
systolic function [58].
Muscular dystrophy
Both Becker and Duchenne muscular dystrophies are
progressive X chromosome-linked recessive neuromuscular
diseases with myocardial involvement in up to 72% of
patients showing a mildly reduced LV function up to severe
LV impairment and dilated CMP. Cardiac myocyte dystro-
phin deficiency leads to necrosis causing replacement of
damaged myocardium by connective tissue and fat in both
ventricles. On CE-CMR, hyperenhancement is predomi-
nantly seen in LV midwall (Fig. 6f) and has been described
in 73–100% of patients [59]. Early diagnosis of myocardial
involvement as assessed with CE-CMR may permit an
earlier treatment of heart failure which could increase life
expectancy.
Chloroquine-induced cardiomyopathy
Chloroquine-induced cardiomyopathy is a rare iatrogenic
disease that is associated with long-term intake of chloro-
quine, which is most frequently prescribed for treatment of
rheumatoid arthritis and malaria prophylaxis [60]. This
CMP is characterised by ineffective lysosomal metabolism
because of an increase in pH that leads to accumulation of
lysosomal glycosphingolipids and finally thickening of
cardiac walls [61]. The time interval between the start of
chloroquine therapy and disease manifestation varies
greatly, ranging from several months to more than 20 years
[60]. CMR may demonstrate the presence of LV hypertro-
phy with accompanying areas of CE in the basal septum
and at the insertion point of the right ventricle (Fig. 6g).
Fabry disease, an X chromosome-linked lysosomal
storage disease caused by a deficient activity of the enzyme
α-galactosidase A, can also result in the accumulation of
glycosphingolipids in multiple organs, including the heart
[61, 62]. Fabry disease cardiomyopathy should therefore
always be considered in the differential diagnosis of
‘idiopathic’ LV hypertrophy (in the absence of arterial
hypertension or valvular disease).
Future developments
Several new strategies for the treatment of the various
forms of cardiomyopathy are currently under development,
including the transplantation of primitive cell types (e.g.,
stem cells or myoblasts) into damaged myocardium in an
attempt to promote trans-differentiation into functional
myocardial cells. CE-CMR imaging can be used to monitor
such studies and to evaluate the results of novel therapeutic
strategies such as direct injection of primitive cell types into
segments with transmural infarction [63]. In animal models,
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mesenchymal stem cells have been labelled with iron-based
contrast agents to examine the process of ‘homing’ of such
cells in the myocardium [64, 65, 66].
Recently, 3.0-T CMR imaging with a 3D inversion-
recovery gradient-echo sequence was compared with
standard 2D imaging. The 3D technique showed superior
spatial image resolution, shorter image acquisition time,
preserved contrast-to-noise ratio, and similar intra- and inter-
observer variabilities (compared with the 2D approach),
which could improve the clinical utility of CE-CMR in the
future [67]. At higher heart rates, though, motion artefacts
can be seen.
Conclusion
Besides its use in patients with ischaemic heart disease, CE-
CMR is increasingly used to establish the diagnosis,
monitor therapy, and obtain prognostic information in a
variety of cardiac diseases. While CE-CMR can provide
valuable information, there is considerable overlap in CE
patterns between different cardiac diseases. For that reason,
CE-CMR findings should be considered in the light of the
clinical history and presentation as well as findings
obtained from other diagnostic modalities.
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